Vanda Strikes Out at the Supreme Court
April 22, 2024, 3:57 PM
Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable expectation of success” standard for patent obviousness that for decades has been a mainstay of patent law.
Vanda argued that the Court should instead adopt a “predictable results” standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda’s petition, leaving the obviousness standard unchanged.

To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
30th Annual IBA Competition Conference
Speaking Engagement
Antitrust
Axinn Represents Modular in $4 Billion Acquisition by Qualcomm
Deals & Cases
Antitrust
Will New DOJ Timing Agreement Deliver Faster Merger Clearances?
Axinn Viewpoints
Antitrust
Why U.S. Regulators Are Cracking Down on Private Equity Investments in the Healthcare Sector
Byline Articles
Antitrust
Women Leaders in Life Sciences Law
Speaking Engagement
Litigation & Trials
American Bar Association: Inside Antitrust Enforcement—Former Government Perspectives
Webinar
Antitrust
What's the Skinny on SCOTUS' Skinny Label Decision?
Webinar
Intellectual Property
National Bar Association Corporate Counsel Leadership Summit
Speaking Engagement
Antitrust
FTC Prescribes Lower Out-of-Pocket Insulin Costs in Settlement with Caremark
Axinn Viewpoints
Antitrust
The FTC’s Record $12 Million HSR Penalty: Deal Structuring, Avoidance, and the Line Between Them
Axinn Viewpoints
Antitrust

